WTR: Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity

Water Tower Research’s new research report takes a close look at how eXoZymes is moving from a promising scientific platform toward a potentially scalable commercial business. 

The report identifies NCT as the company’s most important near-term opportunity and highlights the dramatic progress made in taking it from laboratory development toward commercial production. It also explores the much larger opportunity behind the platform - including potential pharmaceutical applications, cannabinoids, santalene and a pipeline of new molecules - while outlining the milestones that could determine how quickly eXoZymes can turn its technology into partnerships, products and revenue. 


7 things to know from the report:

• eXoZymes is moving from scientific validation toward commercial validation.
• NCT has emerged as the company’s key near-term commercial opportunity.
• The company has made significant progress in improving the economics of NCT production.
• Curia Global is now helping take the technology beyond pilot-scale production.
• The report sees substantial longer-term potential in pharmaceutical applications of the platform.
• Cannabinoids, santalene and five new molecules add further pipeline optionality.
• The next major milestones are scale-up, commercial partnerships, and turning technical progress into revenue.

For investors looking to understand what has changed at eXoZymes, where the company is heading, and what needs to happen next, the report provides a timely look at the company’s evolving strategy and commercial opportunity.

Read the full report here - available with free login!

Paid Research Disclosure
This report was commissioned by and prepared with compensation from eXoZymes Inc. by Water Tower Research. The report reflects the independent views and opinions of Water Tower Research and is intended for informational purposes only. It should not be construed as an offer to sell, or a solicitation of an offer to buy, any securities. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decision. Please refer to the full report for additional disclosures, including potential conflicts of interest.